Yahoo! FinanceHome - Yahoo! - Help

Market Guide

[ Stock Screener | Company & Fund Index | Financial Glossary ]

Profile - Onyx Pharmaceuticals Inc. (NasdaqNM:ONXX)
As of 31-Aug-2001
Enter symbol:
symbol lookup

 
More Info: Quote | Chart | News | Profile | Research | SEC | Msgs | Insider | Options | Financials | Reports
Recent Events
Aug  8Earnings Announcement
Location
3031 Research Drive
Richmond, CA 94806
Phone: (510) 222-9700
Fax: (510) 222-9758
Email: ir@onyx-pharm.com
Employees (last reported count): 135
Financial Links
 ·Top Institutional Holders
 ·Top Mutual Fund Holders
 ·Analyst Upgrade/Downgrade History
 ·Historical Quote Data
 ·Free Annual Report
 ·Raw SEC Filings at sec.gov
Competitors:
 ·Sector: Healthcare
 ·Industry: Biotechnology & Drugs
Company Websites
 ·Home Page
 ·Investor Relations
 ·Yahoo! Category

 ·Search Yahoo! for related links...

Ownership
·Insider and 5%+ Owners: 30%
·Institutional: 17% (24% of float)
(64 institutions)
·Net Inst. Selling: 602.0K shares (+23.68%)
(prior quarter to latest quarter)
More From Market Guide
 ·Highlights
 ·Performance
 ·Ratio Comparisons
Business Summary
Onyx Pharmaceuticals, Inc. is developing products for the treatment of cancer. Based on its proprietary virus technology, the Company is developing its lead product, CI-1042. CI-1042 is a human virus genetically engineered to selectively replicate in and kill cancer cells based on the mutation or loss of function of a specific tumor-suppressor gene, the p53 gene. The Company has completed two Phase II clinical trials of CI-1042, and based on the data from these trials, it has initiated a 300-patient, multi-center Phase III clinical trial of CI-1042, administered by direct injection into tumors, or intratumoral injection, in patients with head and neck cancer. This Phase III clinical trial is being conducted in conjunction with Warner-Lambert Company, a subsidiary of Pfizer, Inc., its collaborator for the development and commercialization of CI-1042.
More from Market Guide: Expanded Business Description

Financial Summary
ONXX is engaged in the discovery and development of novel therapeutics, including both small molecule drugs and therapeutic viruses based upon the genetics of human disease with an emphasis on cancer. For the six months ended 6/30/01, revenues fell 32% to $10.1 million. Net loss totaled $11.1 million, up from $242 thousand. Revenues reflect the absence of the payment from Warner-Lambert. Higher loss also reflects increased clinical trial and contract manufacturing expenses.
More from Market Guide: Significant Developments

Officers[Insider Trade Data]
FY1999 Pay

Hollings Renton, 53
Chairman, Pres, CEO
$383K
Judith Blakemore, 51
Acting COO
--  
Helen Kim, 37
Sr. VP, Clinical Devel.
--  
Leonard Post
Sr. VP, R&D
--  
Thomas Dubensky
VP, Virology
--  
Dollar amounts are as of 31-Dec-1999 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc..
More from Market Guide on Officers & Directors:
Expanded List, Bios, Compensation, Options
Statistics at a Glance -- NasdaqNM:ONXXAs of 31-Aug-2001
Price and Volume
52-Week Low
on 3-Apr-2001
$5.00 
Recent Price$6.38 
52-Week High
on 5-Sep-2000
$28.938
Beta1.06 
Daily Volume (3-month avg)111.6K
Daily Volume (10-day avg)84.0K
Stock Performance
[one-year price graph]
big chart [1d | 5d | 3m | 6m | 1y | 2y | 5y | max]
52-Week Change-76.7%
52-Week Change
relative to S&P500
-68.8%
Share-Related Items
Market Capitalization$118.1M
Shares Outstanding18.5M
Float13.0M
Dividends & Splits
Annual Dividendnone 
Last Splitnone 
Per-Share Data
Book Value (mrq)$3.84 
Earnings (ttm)-$1.07 
Earnings (mrq)-$0.32 
Sales (ttm)$1.14 
Cash (mrq)$3.95 
Valuation Ratios
Price/Book (mrq)1.66 
Price/EarningsN/A 
Price/Sales (ttm)5.62 
Income Statements
Sales (ttm)$19.4M
EBITDA (ttm)-$19.7M
Income available to common (ttm)-$18.4M
Profitability
Profit Margin (ttm)-94.6%
Operating MarginN/A 
Fiscal Year
Fiscal Year EndsDec 31
Most recent quarter30-June-2001
Management Effectiveness
Return on Assets (ttm)-26.10%
Return on Equity (ttm)-31.61%
Financial Strength
Current Ratio (mrq)5.73 
Debt/Equity (mrq)0 
Total Cash (mrq)$73.2M
Short Interest
As of 8-Aug-2001
Shares Short459.0K
Percent of Float3.5%
Shares Short
(Prior Month)
548.0K
Short Ratio3.59 
Daily Volume128.0K
See Profile Help for a description of each item above;   K = thousands;   M = millions;   mrq = most-recent quarter;   ttm = trailing twelve months;   (as of 30-June-2001)

Market Guide offers more in-depth Company Research, Stock Screening, and Hottest Stocks and Industries on over 10,000 U.S. Equities.


Copyright © 2001 Yahoo! Inc. All Rights Reserved. Privacy Policy - Terms of Service
Company information Copyright Market Guide. Historical chart data and daily updates provided by Commodity Systems, Inc. (CSI). Event data provided by CCBN. Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Yahoo nor any of its data or content providers (such as Market Guide, CSI, etc.) shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon.